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| INTRODUC TI ON
Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers, with an estimated 2 093 876 new lung cancer cases that will occur worldwide in 2018. 1 According to National Cancer Center, the incidence and mortality rates of lung cancer in China are very high, and they are increasing year by year. 2 Over the recent years, the treatment strategies for advanced and metastatic NSCLC have been dramatically changed. Immune checkpoint inhibitors (ICIs), including programmed death 1 (PD-1) inhibitors (nivolumab, pembrolizumab) and programmed cell death ligand-1 (PD-L1) inhibitors (atezolizumab) monotherapy or combined chemotherapy have become one of the standard treatments for NSCLC patients without treatable driver mutations. [3] [4] [5] [6] [7] Nivolumab (a fully human IgG4 PD-1 antibody) is the first ICIs to be approved for previously treated advanced NSCLC. 3, 4 Despite the improved survival benefit with ICIs compared with conventional chemotherapy, but a considerable proportion of NSCLC patients still failed to respond. [8] [9] [10] [11] [12] Up to date, PD-L1 and tumor mutational burden (TMB) were used to screen patients who would potentially benefit from ICIs, but they are not the ideal biomarker due to different test platform, panel, cutoff value and many patients could not provide sufficient tumor tissue for testing. Explore markers to predict the clinical outcomes of checkpoint inhibitors have high unmet needs. 13 Inflammation is an important feature of tumor microenvironment and associated with poor prognosis of various types of tumor. 14 Hematological inflammatory parameters such as neutrophil, lymphocyte, monocytes, and platelets can reflect the immune status and have important predictive value for the prognosis of tumors. 15, 16 Some studies have evaluated the value of some blood cell count indexes, particularly the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and demonstrated these biomarkers have the prognostic role in different tumors include NSCLC. [17] [18] [19] [20] [21] [22] [23] [24] Recently, several studies suggested that NLR and PLR also strongly associated with poor clinical outcomes in patients treated with ICIs. [25] [26] [27] [28] Systemic immune-inflammation index (SII) is a novel inflammatory marker which combines NLR and platelet is an independent risk factor for the development of solid cancer. 29 Higher SII was independently associated with worse outcomes for metastatic renal cell carcinoma (RCC) patients treated with nivolumab. 30 However, rare studies reported whether SII is associated with the prognosis of NSCLC patients treated with ICIs.
Consequently, the aim of this retrospective study was to examine the correlation between SII and efficacy in patients with NSCLC treated with ICIs.
| MATERIAL S AND ME THODS

| Study population
Patients with advanced or metastatic NSCLC treated with nivolumab monotherapy for second-line or further-line treatment at the Jilin Cancer Hospital between March 2016 and July 2018 were enrolled in this study.
Data were analyzed by professional statisticians; treatment records were evaluated by clinical experienced doctors; all information were extracted in accordance with uniform requirements. The electronic medical records of patients were reviewed, and all patients had complete blood parameters collected on the date of initial clinic visit or within 7 days prior to starting nivolumab. The last follow-up was on November 9, 2018.
This study was approved by Jilin Cancer Hospital ethic committee. In addition, all patients have signed the informed consent before receiving the nivolumab treatment.
| Determination of efficacy, immune-related adverse reactions and SII, NLR, PLR
Low-dose computed tomography (LDCT)/magnetic resonance imaging (MRI) scan examinations were performed every 6 weeks. Responses to treatment were evaluated based on Response Evaluation Criteria of Solid Tumor (RECIST) ver.1.1, 31 and they were categorized as progressive disease (PD), stable disease (SD), partial remission (PR), and complete remission (CR) according to the therapeutic effect evaluated in the medical record. Toxicity assessment was performed according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Immune-related adverse events (irAEs) were defined as adverse events with a potential immunologic basis that required frequent monitoring and potential intervention with immune suppression or endocrine therapy. 32, 33 IrAEs were determined and graded independently by two experienced physicians and re-evaluated according to the course record. The onset time and end time of irAE were recorded according to management of immunotherapy-related toxicities NCCN 2018 Version 1. A third higher level physician examined the information above. All disagreements were resolved by discussion between three doctors until the consensus was reached. SII = platelet count × neutrophil count/lymphocyte count. The NLR was defined as the absolute number of neutrophils divided by the absolute number of lymphocytes, the PLR as the absolute number of platelets by the absolute number of lymphocytes.
| Statistical analyses
Overall survival (OS) was defined as the interval from treatment initiation until death. Patients who were still alive were censored at the 
| RE SULTS
| Patients
A total of 44 patients with advanced NSCLC treated with nivolumab (3 mg/kg, every 2 weeks) were enrolled in this study. The median age at diagnosis was 60 (range: 43-74) years with 33 (75%) men. PD-1/ PD-L1 status of all patients was unknown. Baseline characteristics of patients are presented listed in Table 1 .
| Treatment response and survival
The median follow-up time was 6.9 m (range: 0.6-28.5 
| The association between hematological inflammatory parameters and PFS/OS
According to the ROC curve, the optimal cutoff value of SII predicted PFS and OS was 603.5, the sensitivity of this point was 0.89, the specificity was 0.67, and the AUC was 0.83. Patients were divided into two groups according to the optimum cutoff value of SII, 22 patients in low SII group (SII ≤ 603.5) and 22 Figure 2A ,B).
The optimal cutoff value of PLR predicted PFS and OS was 144, Figure 3A ,B).
| The association between hematological inflammatory parameters and irAEs
A total of 15 (34.1%) patients developed irAEs. Grade and duration of irAEs for different treatment regimens are shown in Table 2 .
The most common irAEs were hypothyroidism (n = 6, 13.6%) followed by hyperthyroidism (n = 5, 11.4%). Grade 3 or higher irAE was observed in 1 case (2.3%), which was pneumonia. irAE leading to discontinuation were reported in 2 cases, with 1 case of grade 2 pneumonia, and 1 case of grade 2 AST elevation. No irAE-related deaths occurred.
The relationship between SII/NLR/PLR and irAE was also analyzed, but we found there were no statistically significant. (For SII and irAE: P = 0.738; For NLR and irAE: P = 0.665; For PLR and irAE: P = 0.814). 
| Univariate and multivariate analyses
| D ISCUSS I ON
ICIs have become one of the important treatment strategies for NSCLC. Inflammatory cells have important effects on tumor development and systemic inflammation markers can be of use in determining prognosis. 34 In this study, we found that SIIs, NLR, PLR were significantly associated with the prognosis of metastatic NSCLC patients treated with nivolumab for second-line or further-line treatment.
Inflammation is regarded as an important factor in tumor progression and is one of the hallmarks of cancer. 35 In addition, inflammation can supply the tumor microenvironment with bioactive molecules and the products of inflammatory processes can be considered as potential biomarkers. [36] [37] [38] Numerous studies have elucidated in hematological markers, the NLR and PLR can reflect inflammation and host immune reaction, high pretreatment NLR and/or PLR level are potential prognostic predictor for poor PFS and OS in RCC, 26 melanoma, 39 gastric cancer 40 and NSCLC patients received ICIs, 27, 41, 42 some meta-analysis 43, 44 results also demonstrated this conclusion. 
| CON CLUS IONS
Our study demonstrated that at baseline, SII, NLR, and PLR are an independent prognostic predictor in advanced NSCLC patients with the efficacy of nivolumab. These results also offer potential predictive biomarkers and cutoff values to be explored further. In the future, these hematologic parameters could also be used to help stratify patients in randomized studies of ICIs.
ACK N OWLED G M ENTS
The authors thank all patients who participated in this study.
E TH I C A L A PPROVA L
For this type of study, formal consent is not required.
O RCI D
Ying Cheng https://orcid.org/0000-0002-8940-8445 
